“Designing a device to achieve such precision and maintain it over a lifetime requires integration of biology and engineering at a staggering level.” This is how Associate Professor Christopher M. Jewell commented on research on a synthetic pulmonary valve enabling ETR, including Xeltis’ contribution, in Science – Translational Medicine.
“The valves maintained good cardiac function, and, importantly, became increasingly tissue-like when implanted as replacement pulmonary valves,” he added. “Entirely synthetic valves do not require cells or biological matrices but lead to the formation of adaptable, living tissue as the polymer degrades. Effectively translating this idea to the clinic might just keep your heart from skipping a beat.”
Science – Translational Medicine selected a paper just published in Biomaterials as its latest issue’s Editor’s Choice: ‘50 shades of red’. The study included results from a 12-month preclinical study on a bioabsorbable pulmonary valve, conducted by a joint research team including Xeltis.
“Independent research has demonstrated the success of the ETR approach in vivo. Our pulmonary valve is now in clinical trials, getting us even closer to the future of heart valve replacement,” said Xeltis CTO and study co-author, Martijn Cox. “The article is a significant recognition for our cutting-edge technology and the potential of ETR.”
Click here to access the editorial.
